Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) has earned an average rating of “Hold” from the twenty research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $14.50.

MDRX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, April 19th. Deutsche Bank AG raised shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and raised their price target for the company from $12.50 to $14.00 in a research report on Friday, March 24th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a “neutral” rating and set a $13.00 price target on shares of Allscripts Healthcare Solutions in a research report on Wednesday, March 22nd. Citigroup Inc. raised shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research report on Friday, March 24th. They noted that the move was a valuation call. Finally, Jefferies Group LLC reissued a “buy” rating and set a $16.50 price target on shares of Allscripts Healthcare Solutions in a research report on Wednesday, March 22nd.

Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) traded down 1.00% during midday trading on Tuesday, reaching $12.88. 2,123,945 shares of the company’s stock traded hands. The stock has a 50 day moving average of $12.13 and a 200-day moving average of $11.85. The stock’s market cap is $2.34 billion. Allscripts Healthcare Solutions has a 12 month low of $9.80 and a 12 month high of $15.17.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings results on Thursday, May 4th. The software maker reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Allscripts Healthcare Solutions had a negative net margin of 2.93% and a positive return on equity of 5.75%. The company had revenue of $415 million for the quarter, compared to analyst estimates of $415.20 million. During the same period last year, the firm earned $0.13 earnings per share. The firm’s revenue was up 20.1% on a year-over-year basis. On average, equities research analysts forecast that Allscripts Healthcare Solutions will post $0.62 EPS for the current fiscal year.

In other Allscripts Healthcare Solutions news, President Richard J. Poulton sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $12.06, for a total value of $301,500.00. Following the completion of the transaction, the president now directly owns 412,488 shares in the company, valued at $4,974,605.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.75% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. FNY Partners Fund LP raised its stake in shares of Allscripts Healthcare Solutions by 900.0% in the first quarter. FNY Partners Fund LP now owns 8,000 shares of the software maker’s stock worth $101,000 after buying an additional 7,200 shares in the last quarter. Invictus RG purchased a new position in Allscripts Healthcare Solutions during the first quarter valued at approximately $105,000. GSA Capital Partners LLP purchased a new position in Allscripts Healthcare Solutions during the fourth quarter valued at approximately $118,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Allscripts Healthcare Solutions by 9.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,434 shares of the software maker’s stock valued at $120,000 after buying an additional 816 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Allscripts Healthcare Solutions by 60.2% in the first quarter. Bank of Montreal Can now owns 9,914 shares of the software maker’s stock valued at $126,000 after buying an additional 3,724 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Allscripts Healthcare Solutions, Inc. (MDRX) Given Average Rating of “Hold” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/11/allscripts-healthcare-solutions-inc-mdrx-given-average-rating-of-hold-by-brokerages.html.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.